Hosted on MSN18d
EMA approves Takeda’s Takhzyro pre-filled pen option for HAE
The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of Takeda’s Takhzyro (lanadelumab), aimed at treating hereditary ...
Business Insider20d
Takeda announces EMA approval for Takhzyro two mL pre-filled pen option
Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolescents and adult patients with Hereditary Angioedema.